Kwon Young-soo

Professor Kwon Young-soo is a faculty member in the Department of Life Sciences and Department of Bio-Convergence Engineering at Sejong University, where he leads the Genomics Lab. His research integrates next-generation sequencing and bioinformatics to study gene expression regulatory networks in human embryonic stem cells and differentiated cell types, focusing on molecular mechanisms of human development and disease.

His academic background includes:

• Bachelor's degree in Genetic Engineering from Korea University
• Master's degree in Biochemistry from KAIST
• Ph.D. in Biochemistry from KAIST
• Postdoctoral Fellowship in Genomics at University of California, San Diego

Professor Kwon's research spans genomics, RNA biology, and stem cell systems, with emphasis on microRNA function, splicing regulation, and ribonucleoprotein condensates. His Genomics Lab employs cutting-edge DNA analysis technologies to investigate molecular pathways in embryonic stem cell differentiation, contributing to understanding developmental disorders and cancer mechanisms through computational and experimental approaches.

Analysis of his 12 publications (2011-2024) reveals a consistent trajectory in RNA processing mechanisms, featuring prominent work on U2AF1/ZRSR2 splicing elements, L1TD1-mediated condensate dissolution, and microRNA-target networks in stem cells. His research bridges genomic technology development with biological discovery, primarily published in high-impact journals like Nucleic Acids Research and FASEB Journal.

Scientific awards were not documented in the source materials.

Details regarding specific research grants and student advising activities were not provided in available sources, though his active publication record and lab leadership indicate ongoing mentorship and funding.

The Genomics Lab maintains specialized facilities for next-generation sequencing and bioinformatics analysis, with resource links to critical databases including miRBase, Nature, and Cell. Current work shows expanding focus on neurodegenerative disease mechanisms through recent patent applications involving L1TD1 protein therapeutics.